Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

X
Drug Profile

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUO

Latest Information Update: 09 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WuXi Biologics
  • Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Hodgkin's disease
  • Phase III Gastrointestinal cancer; Non-small cell lung cancer
  • Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
  • Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
  • No development reported Cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences
  • 01 Jun 2024 Efficacy and adverse events data from the phase II EDGE-Gastric trial in Gastrointestinal cancer released by Gilead Sciences and Arcus Biosciences
  • 28 May 2024 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top